Jinqi Xue

36 Sanhao Street
Shenyang, 110004, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Erratum: CEMIP as a potential biomarker and therapeutic target for breast cancer patients: Erratum.

Erratum: CEMIP as a potential biomarker and therapeutic target for breast cancer patients: Erratum.

Journal: International journal of medical sciences

Published: October 06, 2025

Correction: Association of human breast cancer CD44-/CD24- cells with delayed distant metastasis.

Correction: Association of human breast cancer CD44-/CD24- cells with delayed distant metastasis.

Journal: eLife

Published: September 10, 2025

Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study.

Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study.

Journal: eLife

Published: July 28, 2025

Correction: Binding blockade between TLN1 and integrin β1 represses triple-negative breast cancer.

Correction: Binding blockade between TLN1 and integrin β1 represses triple-negative breast cancer.

Journal: eLife

Published: May 08, 2025

Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer.

Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer.

Journal: Molecular cancer

Published: April 14, 2025

Erratum to: FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway.

Erratum to: FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway.

Journal: Science China. Life sciences

Published: March 18, 2025

Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial.

Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial.

Journal: Nature communications

Published: February 19, 2025

Neoadjuvant chidamide combined with chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (MUKDEN 05): a multicentre, single-arm, phase 2 trial.

Neoadjuvant chidamide combined with chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (MUKDEN 05): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet regional health. Western Pacific

Published: January 30, 2025

Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options.

Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options.

Journal: Molecular cancer

Published: February 03, 2024

Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer.

Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer.

Journal: Molecular cancer

Published: January 05, 2024

FOXQ1, deubiquitinated by USP10, alleviates sepsis-induced acute kidney injury by targeting the CREB5/NF-κB signaling axis.

FOXQ1, deubiquitinated by USP10, alleviates sepsis-induced acute kidney injury by targeting the CREB5/NF-κB signaling axis.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: November 22, 2023

MAGP2 promotes osteogenic differentiation during fracture healing through its crosstalk with the β-catenin pathway.

MAGP2 promotes osteogenic differentiation during fracture healing through its crosstalk with the β-catenin pathway.

Journal: Journal of cellular physiology

Published: October 12, 2023

Showing 1-12 of 40

Last Updated: 09/26/2026